J Cancer Metastasis TreatJournal of Cancer Metastasis and Treatment2454-2857OAE Publishing Inc.10.20517/2394-4722.2018.74EditorialIntroduction to this special issue - “Autophagy and Cancer: current biology and drug development”https://orcid.org/0000-0003-4181-1435acheung@mail.ncku.edu.twCheungChun Hei Antonio121Department of Pharmacology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.2Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.Correspondence Address: Prof. Chun Hei Antonio Cheung, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan. E-mail: acheung@mail.ncku.edu.tw
Received: 14 Nov 2018 | First Decision: 28 Nov 2018 | Revised: 5 Dec 2018 | Accepted: 10 Dec 2018 | Published: 9 Aug 2019
Science Editor: Chun Hei Antonio Cheung | Copy Editor: Jia-Jia Meng | Production Editor: Tian Zhang
It is my pleasure, as one of the editorial board members, to introduce the readers of JCMT to this special issue entitled “Autophagy and Cancer: current biology and drug development”.
Autophagy is a fundamental process for cells to degrade unwanted proteins/damaged organelles and also to recycle cellular components. Since its discovery on 1960’s, a vast amount of effort has been made in understanding the physiological role/s of this process. For example, it is now known that mitosis, apoptosis, and autophagy are inter-connected and inter-regulated in cells[1]. It is also known that upregulation of autophagy is a double-edged sword that promotes both cell survival and cell death, depending on the circumstances. However, the pathological role/s of autophagy in normal-to-cancer cell transformation, tumor development, and tumor drug resistance was not clear until the arrival of various breakthrough discoveries in the past 15 years. Noticeably, it has been demonstrated that dysregulation of autophagy (and probably downregulation) induces genomic instability in non-cancerous cells and subsequently promotes tumorigenesis[2]. In contrast, upregulation of autophagy has been shown to enhance the survival ability of cancer cells in response to various micro-environmental stresses and different chemotherapeutic agents[3]. Therefore, autophagy is currently a “hot” cellular pathway target for the development of cancer therapeutics[4-7].
This special issue contains reviews focusing on recent understandings on the regulation of autophagy in non-cancerous cells and dysregulation of this process in cancer cells. Reviews on recent advances in the development of autophagy modulators for cancer treatment are also included in this special issue.
DeclarationsAuthors’ contributions
Manuscript drafting: Cheung CHA.
Availability of data and materials
Not applicable.
Financial support and sponsorship
None.
Conflicts of interest
All authors declared that there are no conflicts of interest.
ThorburnAApoptosis and autophagy: regulatory connections between two supposedly different processes.2008131910.1007/s10495-007-0154-917990121PMC2601595BrechAAhlquistTLotheRAStenmarkHAutophagy in tumour suppression and promotion.200933667510.1016/j.molonc.2009.05.00719559660PMC5527946Prieto-DomínguezNOrdóñezRFernándezAGarcía-PalomoAMuntanéJModulation of Autophagy by Sorafenib: Effects on Treatment Response.2016715110.3389/fphar.2016.0015127375485PMC4896953DuffyALeJSausvilleEEmadiAAutophagy modulation: a target for cancer treatment development.2015754394710.1007/s00280-014-2637-z25422156JanjiBBerchemGChouaibSTargeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.2018988710.3389/fimmu.2018.0088729922284PMC5996896LeeJYCKuoCWTsaiSLChengSMChenSHInhibition of HDAC3- and HDAC6-Promoted Survivin Expression Plays an Important Role in SAHA-Induced Autophagy and Viability Reduction in Breast Cancer Cells.201678110.3389/fphar.2016.0008127065869PMC4814469KaliszczakMvan HechanovaELiYAlsadahHParzychKThe HDAC6 inhibitor C1A modulates autophagy substrates in diverse cancer cells and induces cell death.201811912788710.1038/s41416-018-0232-530318510PMC6251030